Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/2a25fcdb-951e-4695-ac2e-c22b3d508cde/

PCRX

Pacira BioSciences, Inc.
Chart
26.41 USD
Latest Week 2026-07-31
HealthcareDrug Manufacturers - Specialty & GenericSMALL
Snapshot 2026-07-26 · 1.0w · Fresh
0.36
OS Score
29.0%
Value
79.0%
Quality
34.0%
Momentum
8/9
F-Score
0.479
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
3 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
9.2%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
19.2%
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.60
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
29.0%ile
P/E
198.2×
P/S
1.4×
P/B
1.6×
E/P
0.0212
FCF Yield
0.118
EBITDA/EV
0.092
SH Yield
0.192
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
33.00000000
/100 — 1=cheapest
VC2 (Trending Value)
23.00000000
/100
VC3 (Buyback)
24.00000000
/100
P/E of 198.2x is premium-priced — the market is paying up for expected growth. FCF yield of 11.8% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
79.0%ile
ROE
0.008
ROA
0.004
Net Margin
0.007
Op Margin
0.037
GPA
0.482
D/E
0.85
Current
4.73
F-Score
8/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.046
Stability
4.345
lower=better
Accruals
-0.113
lower=better
5yr Consist
No
F-Score of 8/9 indicates strong fundamental improvement across multiple dimensions.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
34.0%ile
6M Return
25.2%
12M Return
14.8%
12-1 Mom
11.9%
Risk-Adj
0.30
Vol 252d
39.3%
Vol 60d
85.7%
↑ Expanding
Max DD 12M
-29.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (86%) is expanding vs long-term (39%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.36
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
8.6%
Sector Quality %ile
84.2%
P/E z-score
3.00
P/B z-score
-0.24
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
PBYI Puma Biotechnology Inc 97.0% 79.0% 97.0% 96.0%
Factor Interactions
Strong Capital Return
Shareholder yield 19.2% backed by 11.8% FCF yield. Returns are well-funded.
Quality at a Premium
High quality (79th) but expensive (29th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (86%) significantly exceeds 252-day (39%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
62.5% avg (7 factors)
Quality
C
52.9% avg (8 factors)
Momentum
C
50.1% avg (4 factors)
Risk
C
51.1% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.360—0—
Value %ile0.290—5—
Quality %ile0.790—8—
Momentum %ile0.340—0—
F-Score8.000—8—
Confidence0.900—8—
Volatility0.393—0—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
198.19
Earnings Yield (E/P)
0.0212
Price / Sales
1.39
Price / Book
1.56
Price / Cash Flow
7.16
FCF Yield
11.8%
EBITDA / EV
9.2%
Sales Yield (1/P·S)
0.5718
Shareholder Yield
Div + net buyback / mktcap
19.2%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
0.8%
Return on Assets
0.4%
Net Margin
0.7%
Operating Margin
3.7%
Gross Profit / Assets
Novy-Marx GPA
48.2%
Debt / Equity
0.85
Current Ratio
4.73
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.113
External Financing
Net issuance — lower=better
0.167
MomentumPrice trend strength over different horizons
6M Return
25.2%
12M Return
14.8%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
11.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.30
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
4.6%
Earnings Stability (CV)
Lower = more stable
4.345
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
8
Buyback Yield
19.2%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
33
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
23
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
24
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity